Fresenius Medical Care (FMS) starts EUR 1B share buyback with EUR 600M first tranche
Rhea-AI Filing Summary
Fresenius Medical Care has launched a new share buyback program with a total volume of up to EUR 1 billion, returning capital to shareholders under an authorization granted on May 21, 2026. The program runs for 12 months from May 28, 2026 to May 27, 2027 and allows repurchase of up to 29,341,344 shares on the stock exchange or via a multilateral trading facility.
The first tranche covers purchases of up to EUR 600,000,000 through December 15, 2026. Repurchased shares are predominantly intended to be cancelled, with a smaller portion available for incentive-based compensation. Purchases must comply with EU safe-harbor rules, including price caps relative to the last independent trade and limits of no more than 25% of average daily share turnover.
Positive
- None.
Negative
- None.
Insights
Fresenius Medical Care launches a sizeable, regulated EUR 1 billion share buyback, starting with a EUR 600 million first tranche.
The company has authorized a share buyback program of up to EUR 1 billion, with capacity to repurchase up to 29,341,344 shares over 12 months. The first tranche, up to EUR 600,000,000, is scheduled to run until December 15, 2026 and will be executed by a mandated credit institution acting independently.
The authorization permits acquisitions of up to 10% of share capital until May 20, 2031, corresponding to 26,856,463 shares at present. Purchases must follow EU safe-harbor rules, including strict price bands around the opening auction price and daily volume limits of no more than 25% of average daily share turnover over the prior 20 trading days.
Transactions will be disclosed no later than the end of the seventh trading day after execution, and the company plans regular updates on its investor website, where information about the buyback will be available for at least five years from public disclosure. The impact for shareholders will depend on the pace of execution and the extent of share cancellation versus use for incentive-based compensation.
Key Figures
Key Terms
safe-harbor-provisions regulatory
Delegated Regulation (EU) 2016/1052 regulatory
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What did Fresenius Medical Care (FMS) announce in its May 2026 6-K?
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER
Pursuant to Rule 13a-16 or 15d-16 of the
Securities Exchange Act of 1934
For the month of May 2026
Commission file number: 001-32749
FRESENIUS MEDICAL CARE AG
(Translation of registrant's name into English)
Else-Kröner-Strasse 1
61346 Bad Homburg
Germany
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F x Form 40-F ¨
EXHIBITS
The following exhibits are being furnished with this Report:
| Exhibit 99.1 | Convenience translation of the disclosure pursuant to Art. 5 para. 1 lit. a) of Regulation (EU) No. 596/2014 and Art. 2 para. 1 of Delegated Regulation (EU) 2016/1052. |
| This disclosure does not constitute an offer to purchase or a solicitation of any offer to sell any securities. | |
| Exhibit 99.2 | Press Release issued on May 28, 2026. |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
DATE: May 28, 2026
| Fresenius Medical Care AG | ||
| By: | /s/ Helen Giza | |
| Name: | Helen Giza | |
| Title: | Chief Executive Officer and Chair of the Management Board | |
| By: | /s/ Martin Fischer | |
| Name: | Martin Fischer | |
| Title: | Chief Financial Officer and member of the Management Board | |
Exhibit 99.1
Bad Homburg v.d. Höhe, May 28, 2026
Disclosure pursuant to Art. 5 para. 1 lit. a) of Regulation (EU) No 596/2014 and Art. 2 para. 1 of Delegated Regulation (EU) 2016/1052
Fresenius Medical Care AG ("FME") disclosed on May 26, 2026, to conduct the next share buyback program. The program is scheduled to commence on May 28, 2026, and to be completed within 12 months by May 27, 2027 (inclusive). Up to 29,341,344 shares (ISIN DE0005785802, "FME-Shares") may be repurchased on the stock exchange or via a multilateral trading facility within the meaning of Section 2 para. 6 of the German Stock Exchange Act (Börsengesetz) for a total purchase price of up to EUR 1 billion (not including ancillary acquisition costs). The purchase of FME-Shares and the maximum number of FME-Shares to be acquired are based on the authorization granted by the General Meeting on May 21, 2026 ("Authorization").
The repurchased FME-Shares are predominantly to be cancelled and the share capital to be reduced accordingly. To a significantly lesser extent, the repurchased FME-Shares may be used for allocations under incentive-based compensation plans.
The buyback shall be made in tranches. Under the first tranche, FME-Shares shall be acquired for a total amount of up to EUR 600,000,000 (not including ancillary acquisition costs) over a period ending on December 15, 2026 (inclusive) under the following conditions.
The buyback shall be carried out in accordance with the safe-harbor-provisions of Art. 5 of Regulation (EU) No 596/2014 in conjunction with the provisions of Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 supplementing Regulation (EU) No 596/2014 with regulatory technical standards on the conditions applicable to buyback programs and stabilization measures ("Delegated Regulation (EU) 2016/1052").
A credit institution has been mandated for the first tranche of the buyback. The credit institution makes its trading decisions concerning the timing of the purchases of FME-Shares independently of and without any influence from FME.
Pursuant to the Authorization, FME is allowed to acquire FME-Shares until the end of May 20, 2031, in an amount of up to 10 % of the share capital existing at the time of the resolution. The FME-Shares acquired, together with other treasury FME-Shares held by the Company or attributable to the Company pursuant to Sections 71a et seqq. of the German Stock Corporation Act (Aktiengesetz), must at no time exceed 10 % of the share capital. This currently corresponds to 26,856,463 FME-Shares. The amount paid per FME-Share (not including ancillary acquisition costs) may not exceed the price of FME-Shares of the same class determined by the opening auction in the Xetra trading system (or a functionally equivalent successor to the Xetra system) on the day of trading by more than 10 % or fall short of such price by more than 20 %.
The credit institution will in particular be obligated to carry out the share buyback in compliance with the trading conditions of Art. 3 of Delegated Regulation (EU) 2016/1052. Accordingly, the FME-Shares shall not be purchased at a price higher than the price of the last independent trade or (should this be higher) higher than the current highest independent bid on the trading venue on which the purchase is carried out. In addition, no more than 25 % of the average daily share turnover on the trading venue on which the purchase is made may be purchased on one trading day. The average daily share turnover is calculated on the basis of the average daily trading volume during the 20 trading days preceding the respective purchase date.
The transactions related to the share buyback program will be disclosed in accordance with the requirements of Art. 5 para. 1 lit. b) of Regulation (EU) No 596/2014 no later than by the end of the seventh trading day following the day of execution of such transactions.
FME will provide regular information regarding the progress of the share buyback program, including by posting its required disclosures at https://freseniusmedicalcare.com/en/investors/shares/share-buy-back/, and will keep that information available to the public for at least a 5-year period from the date of public disclosure.
Exhibit 99.2
| Press Release | Media contact Christine Peters T +49 160 60 66 770 christine.peters@freseniusmedicalcare.com
Contact for analysts and investors Dr. Dominik Heger T +49 6172 609 2525 dominik.heger@freseniusmedicalcare.com
www.freseniusmedicalcare.com |
Fresenius Medical Care launches first tranche of its share buyback program of up to EUR 600 million
Bad Homburg (May 28, 2026) – Fresenius Medical Care (FME), the world’s leading provider of products and services for individuals with renal diseases, today announced the launch of the first tranche of its new share buyback program with a total volume of around EUR 1 billion. The first tranche, amounting up to EUR 600 million, was initiated today and is expected to be completed by December 15, 2026.
The share buyback program is part of the Company’s capital allocation framework, complementing dividends and reflecting FME’s commitment to disciplined, value-focused capital management.
The program is based on the authorization to purchase and use treasury shares granted by the Company’s Annual General Meeting on May 21, 2026.
FME will provide regular updates on the progress of the share buyback program at:
https://freseniusmedicalcare.com/en/investors/shares/share-buyback/
Page 1/2
About Fresenius Medical Care:
Fresenius Medical Care is the world's leading provider of products and services for individuals with renal diseases of which around 4.5 million patients worldwide regularly undergo dialysis treatment. Through its network of 3,539 dialysis clinics, Fresenius Medical Care provides dialysis treatments for approx. 290,000 patients around the globe. Fresenius Medical Care is also the leading provider of dialysis products such as dialysis machines or dialyzers. Fresenius Medical Care is listed on the Frankfurt Stock Exchange (FME) and on the New York Stock Exchange (FMS).
For more information visit the company’s website at www.freseniusmedicalcare.com.
Disclaimer:
This release contains forward-looking statements that are subject to various risks and uncertainties. Actual results could differ materially from those described in these forward-looking statements due to various factors, including, but not limited to, changes in business, economic and competitive conditions, legal changes, regulatory approvals, results of clinical studies, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings, and the availability of financing. These and other risks and uncertainties are detailed in Fresenius Medical Care’s reports filed with the U.S. Securities and Exchange Commission. Fresenius Medical Care does not undertake any responsibility to update the forward-looking statements in this release.
Page 2/2